Biora Therapeutics, Inc. (BIOR)
(Delayed Data from NSDQ)
$0.67 USD
+0.01 (0.87%)
Updated Jul 29, 2024 04:00 PM ET
After-Market: $0.67 0.00 (-0.52%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
BIOR 0.67 +0.01(0.87%)
Will BIOR be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for BIOR based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BIOR
Is Butterfly Network (BFLY) Outperforming Other Medical Stocks This Year?
Biora Therapeutics, Inc. (BIOR) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
BIOR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Biora Therapeutics, Inc. (BIOR) Reports Q3 Loss, Misses Revenue Estimates
Fate Therapeutics (FATE) Reports Q3 Loss, Lags Revenue Estimates
Other News for BIOR
Biora Therapeutics Buy Rating Confirmed by Positive Phase 1 Trial Outcomes and NaviCap Technology Potential
Biora Therapeutics Advances Ulcerative Colitis Treatment with BT-600 Trial Success
Biora Therapeutics announces data from Phase 1 trial of BT-600
12 Health Care Stocks Moving In Monday's After-Market Session
Why Ross Stores Shares Are Trading Higher By Over 8%; Here Are 20 Stocks Moving Premarket